Changfeng Pharmaceutical's IPO on the Hong Kong stock market and the domestic unlisted shares have been approved for "full circulation" by the China Securities Regulatory Commission.

The International Cooperation Department of the China Securities Regulatory Commission issued a filing notice regarding the overseas issuance and listing of Changfeng Pharmaceutical Co., Ltd. and the "full circulation" of unlisted shares domestically. The company intends to issue no more than 142,132,481 shares of overseas listed common stock and list on the Hong Kong Stock Exchange. 54 shareholders of the company plan to convert a total of 261,025,586 unlisted shares into overseas listed shares, which will also be listed for trading on the Hong Kong Stock Exchange.